Tyr159
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr159  -  VAV2 (human)

Site Information
HDLGEDIyDCVPCED   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 452201
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 ) , mutation of modification site ( 8 ) , phospho-antibody ( 8 )
Disease tissue studied:
brain cancer ( 2 ) , glioblastoma multiforme ( 2 ) , glioma ( 2 ) , gastric cancer ( 7 ) , hepatocellular carcinoma, surrounding tissue ( 5 ) , lung cancer ( 3 ) , neuroblastoma ( 1 , 6 )
Relevant cell line - cell type - tissue:
COS (fibroblast) ( 8 ) , glial-brain ( 2 ) , HeLa (cervical) ( 4 ) , hepatic-'liver, para-hepatocellular carcinoma tissue' ( 5 ) , KATO III (gastric) ( 7 ) , NCI-H292 (pulmonary) ( 3 ) , SKNFI (neural crest) ( 1 , 6 )

Upstream Regulation
Kinases, in vitro:
EGFR (human) ( 8 )
Treatments:
EGF ( 8 )

References 

1

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

2

Johnson H, et al. (2012) Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts. Mol Cell Proteomics 11, 1724-40
22964225   Curated Info

3

Li J, et al. (2010) A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6, 291-9
20190765   Curated Info

4

Moritz A (2010) CST Curation Set: 9059; Year: 2010; Biosample/Treatment: cell line, HeLa/Peroxide; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Gu T (2009) CST Curation Set: 7521; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Stokes M (2006) CST Curation Set: 1764; Year: 2006; Biosample/Treatment: cell line, SKNFI/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Guo A (2006) CST Curation Set: 1645; Year: 2006; Biosample/Treatment: cell line, KATO III/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Tamás P, et al. (2003) Mechanism of epidermal growth factor regulation of Vav2, a guanine nucleotide exchange factor for Rac. J Biol Chem 278, 5163-71
12454019   Curated Info